These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20961696)

  • 21. Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system.
    Seo Y; Wong KH; Sun M; Franc BL; Hawkins RA; Hasegawa BH
    J Nucl Med; 2005 May; 46(5):868-77. PubMed ID: 15872362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Capromab Pendetide imaging of prostate cancer.
    Haseman MK; Rosenthal SA; Polascik TJ
    Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate.
    El-Zawahry AM; Clarke HS; Eskridge MR; Rieter W; Onicescu G; Garrett-Mayer E; Gordon LL; Keane TE
    Urology; 2010 Nov; 76(5):1162-7. PubMed ID: 20434196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.
    Schuster DM; Nieh PT; Jani AB; Amzat R; Bowman FD; Halkar RK; Master VA; Nye JA; Odewole OA; Osunkoya AO; Savir-Baruch B; Alaei-Taleghani P; Goodman MM
    J Urol; 2014 May; 191(5):1446-53. PubMed ID: 24144687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life.
    Hubosky SG; Fabrizio MD; Schellhammer PF; Barone BB; Tepera CM; Given RW
    J Endourol; 2007 Dec; 21(12):1521-31. PubMed ID: 18186694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy.
    Palma D; Tyldesley S; Blood P; Liu M; Morris J; Pickles T;
    Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1425-9. PubMed ID: 17394943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
    Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Indium-111 capromab pendetide in the management of recurrent prostate cancer.
    Manyak MJ
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):175-81. PubMed ID: 18279057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.
    Aizer AA; Yu JB; McKeon AM; Decker RH; Colberg JW; Peschel RE
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1344-9. PubMed ID: 19464821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease?
    Zapatero A; García-Vicente F; Martín de Vidales C; Cruz Conde A; Ibáñez Y; Fernández I; Rabadán M
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1279-85. PubMed ID: 20932659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland.
    Mouraviev V; Madden JF; Broadwater G; Mayes JM; Burchette JL; Schneider F; Smith J; Tsivian M; Wong T; Polascik TJ
    J Urol; 2009 Sep; 182(3):938-47. PubMed ID: 19616259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
    Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
    Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy.
    Wilkinson S; Chodak G
    J Urol; 2004 Jul; 172(1):133-6. PubMed ID: 15201753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Procedure for unmasking localization information from ProstaScint scans for prostate radiation therapy treatment planning.
    DeWyngaert JK; Noz ME; Ellerin B; Kramer EL; Maguire GQ; Zeleznik MP
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):654-62. PubMed ID: 15380603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
    Ko EC; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection and localization of carcinoma within the prostate using high resolution transrectal gamma imaging (TRGI) of monoclonal antibody directed at prostate specific membrane antigen (PSMA)--proof of concept and initial imaging results.
    Franc BL; Cho SY; Rosenthal SA; Cui Y; Tsui B; Vandewalker KM; Holz AL; Poonamallee U; Pomper MG; James RB
    Eur J Radiol; 2013 Nov; 82(11):1877-84. PubMed ID: 23993140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate specific antigen only progression of prostate cancer.
    Moul JW
    J Urol; 2000 Jun; 163(6):1632-42. PubMed ID: 10799151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
    Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of ProstaScint for brachytherapy in localized prostate adenocarcinoma.
    Ellis RJ; Kim E; Foor R
    Expert Rev Mol Diagn; 2004 Jul; 4(4):435-41. PubMed ID: 15225091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.